Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 20, 2025 /PRNewswire/ -- Equity Insider News Commentary - The World Economic ...

From surgical precision tools to real-time diagnostics, brain-responsive stimulation, and multi-disease detection systems, AI ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Surgeons in southern California successfully completed the world's first-ever human bladder transplant on 41-year-old Oscar ...

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.